Literature DB >> 32734001

MORE THAN MEETS THE EYE IN A PATIENT WITH PCOS: ANDROGEN-SECRETING GRANULOSA CELL OVARIAN TUMOR IN A VIRILIZED WOMAN WITH POLYCYSTIC OVARIAN SYNDROME (PCOS).

Ashley A Harris, Udaya M Kabadi.   

Abstract

OBJECTIVE: Granulosa cell ovarian tumors are known to secrete estrogen. Herein we report a patient presenting with primary amenorrhea and virilization with markedly high androgen levels, all thought to be disproportional to be attributed to polycystic ovary syndrome (PCOS) alone. Bilateral oophorectomy revealed a rare androgen-secreting granulosa cell ovarian tumor and bilateral cysts (PCOS) both contributing to manifestations.
METHODS: Description of a case and discussion of the literature.
RESULTS: A 25-year-old female presented with primary amenorrhea, male pattern baldness and hirsutism of the face and chest, clitoral hypertrophy, cystic acne on the chest and shoulders, and type 2 diabetes. Diagnosis of PCOS was made at age 13 years. The concurrent presence of congenital adrenal hyperplasia was also considered. She was receiving metformin, oral contraceptives, and/or spironolactone with no improvement in manifestations at presentation to the endocrine clinic. She reported several elevated serum testosterone and androstenedione levels. Diagnosis of PCOS was established by the presence of enlarged cystic ovaries on ultrasound examination. The patient reported worsening manifestations including progression of diabetes despite therapy with metformin. She shaved her face, chest, and breasts daily for cosmetic reasons. Laboratory testing demonstrated markedly elevated total testosterone level (234 ng/dL), and normal cortisol and adrenocorticotropic hormone levels. Dexamethasone suppression and human chorionic gonadotropin stimulation indicated ovaries as a probable source of excessive circulating androgen levels. A computed tomography scan of the abdomen and pelvis showed multiple cysts in both ovaries, the largest being 1.9 cm in the right ovary. Due to the severity of manifestations, the patient was counseled to undergo fluoroscopically guided blood sampling of bilateral adrenal and ovarian veins, which confirmed both ovaries to be the source of the excess androgen production with a greater contribution by the right ovary. The patient underwent bilateral oophorectomy. Pathologic examination confirmed the presence of bilateral polycystic ovaries as well as an androgen-secreting granulosa cell tumor in the right ovary which apparently contributed to greater androgen levels in a right ovarian venous blood sample. Peripheral venous androgen levels normalized promptly after bilateral oophorectomy. Gradual resolution of clinical manifestations followed.
CONCLUSION: A unique presentation of granulosa cell ovarian tumor with concurrent PCOS contributing to the extremely excessive production of androgens in a young woman manifesting primary amenorrhea and masculinization at the onset of puberty with marked gradual resolution of manifestations following bilateral oophorectomy.
© 2020 AACE.

Entities:  

Year:  2020        PMID: 32734001      PMCID: PMC7388264          DOI: 10.4158/ACCR-2019-0576

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  13 in total

Review 1.  Androgenic adult granulosa cell tumor in a 13-year-old prepubertal patient: a case report and review of the literature.

Authors:  C Y Castro; A Malpica; R H Hearne; E G Silva; C V Castro
Journal:  Int J Gynecol Pathol       Date:  2000-07       Impact factor: 2.762

2.  Unusual presentation of juvenile granulosa cell tumor of the ovary.

Authors:  D Larizza; V Calcaterra; P Sampaolo; G Lanati; P Brambilla; T Mondello; S Cesari
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

Review 3.  Therapeutic approach for metabolic disorders and infertility in women with PCOS.

Authors:  G Morgante; M G Massaro; A Di Sabatino; V Cappelli; V De Leo
Journal:  Gynecol Endocrinol       Date:  2017-08-29       Impact factor: 2.260

Review 4.  Androgenic adult granulosa cell tumor in a teenager: a case report and review of the literature.

Authors:  C Kabaca; A Karateke; A Gurbuz; S Cesur
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

Review 5.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.

Authors:  Neil F Goodman; Rhoda H Cobin; Walter Futterweit; Jennifer S Glueck; Richard S Legro; Enrico Carmina
Journal:  Endocr Pract       Date:  2015-12       Impact factor: 3.443

Review 6.  Androgen-Secreting Ovarian Tumors.

Authors:  Djuro Macut; Dušan Ilić; Ana Mitrović Jovanović; Jelica Bjekić-Macut
Journal:  Front Horm Res       Date:  2019-09-09       Impact factor: 2.606

7.  Androgenic juvenile granulosa cell tumor of the ovary with cystic presentation: a case report.

Authors:  R S Nomelini; A M R Micheletti; S J Adad; E F C Murta
Journal:  Eur J Gynaecol Oncol       Date:  2007       Impact factor: 0.196

Review 8.  Midlife women's health consequences associated with polycystic ovary syndrome.

Authors:  A T Ali; F Guidozzi
Journal:  Climacteric       Date:  2019-10-28       Impact factor: 3.005

Review 9.  Polycystic Ovary Syndrome.

Authors:  Ricardo Azziz
Journal:  Obstet Gynecol       Date:  2018-08       Impact factor: 7.661

Review 10.  Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.

Authors:  Helena J Teede; Marie L Misso; Michael F Costello; Anuja Dokras; Joop Laven; Lisa Moran; Terhi Piltonen; Robert J Norman
Journal:  Fertil Steril       Date:  2018-07-19       Impact factor: 7.329

View more
  1 in total

1.  The LINC00477/miR-128 axis promotes the progression of polycystic ovary syndrome by regulating ovarian granulosa cell proliferation and apoptosis.

Authors:  Haijie Gao; Jinna Jiang; Yingying Shi; Jiying Chen; Lijian Zhao; Chenhong Wang
Journal:  Reprod Biol Endocrinol       Date:  2021-02-23       Impact factor: 5.211

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.